EPGIX Performance — EuroPac Gold Fund, Class I
Data updated: 2026-09-28
EPGIX returned −9.41% year to date and +41.61% over one year to Jul 2026. Annualised returns are +28.94% over 3 years and +12.98% over 5 years. Against its Europe Materials Equity category average the fund came out ahead over three years but behind over one: $100 invested three years ago grew to $214, against $163 for the category, and to $142 over one year, against $172. Volatility over the past three years was 32.89% a year. In the 12 months to Jul 2026 the fund took in a net $79.2M, and assets reached $507.56M.
EPGIX Growth of $100
What $100 invested in EuroPac Gold Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Europe Materials Equity category average over the same months.
| Period | EPGIX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $142 | $172 |
| 3 years (Aug 2023 – Jul 2026) | $214 | $163 |
| 5 years (Aug 2021 – Jul 2026) | $184 | $149 |
| Since data start (Feb 2020 – Jul 2026) | $223 | $188 |
EPGIX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −9.41% |
| 1 year | +41.61% |
| 3 years (annualised) | +28.94% |
| 5 years (annualised) | +12.98% |
EPGIX Annual Returns
Calendar-year total returns of EuroPac Gold Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | −9.41% |
| 2025 | +129.70% |
| 2024 | +8.84% |
| 2023 | +2.51% |
| 2022 | −13.84% |
| 2021 | −17.79% |
| 2020 (Feb–Dec) | +35.78% |
EPGIX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +10.2% | +19.1% | −19.4% | −0.9% | +3.0% | −13.2% | −3.4% | — | — | — | — | — |
| 2025 | +9.9% | +3.1% | +10.5% | +8.5% | +2.5% | +5.2% | +0.2% | +20.1% | +16.1% | −6.7% | +15.3% | +4.2% |
| 2024 | −7.0% | −6.7% | +17.6% | +4.1% | +9.9% | −7.9% | +9.0% | −0.3% | +3.8% | +5.2% | −6.0% | −9.3% |
| 2023 | +9.5% | −11.5% | +17.9% | +1.8% | −7.7% | −3.0% | +3.9% | −5.8% | −9.5% | −0.7% | +11.1% | +0.6% |
| 2022 | −7.3% | +10.4% | +10.6% | −7.5% | −9.8% | −13.1% | −1.3% | −10.7% | +0.1% | +0.9% | +17.6% | +0.1% |
| 2021 | −6.1% | −9.4% | +1.6% | +5.6% | +12.4% | −13.2% | +0.3% | −6.4% | −8.7% | +10.2% | −3.4% | +1.1% |
| 2020 | — | −15.9% | −13.7% | +36.0% | +12.2% | +6.4% | +19.7% | +3.3% | −8.6% | −4.2% | −4.9% | +12.0% |
EPGIX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 32.89%
- 3-year Sharpe ratio: 0.74 (vs 4.5% risk-free rate)
- Best month: +20.10% (Aug 2025)
- Worst month: −19.38% (Mar 2026)
EPGIX Fund Flows
Monthly money in and out of EuroPac Gold Fund, from SEC Form N-PORT.
- 12-month net flow: $79.2M
- 12-month gross sales (incl. reinvestments): $252.0M
- Sales ÷ redemptions: 1.46×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $4.8M | $5.9M | −$1.2M |
| Jun 2026 | $6.6M | $9.3M | −$2.6M |
| May 2026 | $7.3M | $7.8M | −$501K |
| Apr 2026 | $5.6M | $10.2M | −$4.6M |
| Mar 2026 | $15.5M | $43.0M | −$27.5M |
| Feb 2026 | $28.3M | $24.5M | $3.8M |
| Jan 2026 | $60.6M | $20.3M | $40.4M |
| Dec 2025 | $45.7M | $17.2M | $28.5M |
| Nov 2025 | $6.1M | $7.7M | −$1.6M |
| Oct 2025 | $29.0M | $12.3M | $16.7M |
| Sep 2025 | $28.1M | $8.7M | $19.4M |
| Aug 2025 | $14.4M | $6.0M | $8.5M |
EPGIX Assets Under Management
Net assets of EuroPac Gold Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $507.56M |
| 2026-04-30 | $592.52M |
| 2026-01-31 | $649.49M |
| 2025-10-31 | $472.03M |
| 2025-07-31 | $328.04M |
| 2025-04-30 | $302.66M |
| 2025-01-31 | $230.93M |
| 2024-10-31 | $268.33M |
| 2024-07-31 | $247.06M |
| 2024-04-30 | $227.68M |
| 2024-01-31 | $197.75M |
| 2023-10-31 | $190.93M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.